4,4'-亚甲基二[3-羟基-2-萘甲酸]二钾 | 68226-95-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 4,4'-亚甲基二[3-羟基-2-萘甲酸]二钾
• 英文名称: 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, dipotassium salt
• 英文别名: dipotassium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate
• CAS: 68226-95-9
• 化学式: C23H14K2O6
• 分子量: 464.5
• InChiKey: TXJHTNYUHQATPI-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -4.27
• 重原子数：
  31
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER
  申请人：King Clifford Riley

  公开号：US20120028960A1

  公开（公告）日：2012-02-02

  A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.

  一种药物组合物，包括基本上由含有药用活性化合物的胺的药用可接受的有机酸加合盐组成的药物物质，其中含有药用活性化合物的胺被选择自光学异构体或单异构体利他林酸或苯乙胺衍生物的群体，并且该药物物质具有从无定形到多型的物理形式。
• SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS
  申请人：King Clifford Riley

  公开号：US20140178480A1

  公开（公告）日：2014-06-26

  Drug substances comprising a amine containing pharmaceutically active compound, and at least one of an alditol acetal and an aromatic organic acid as an addition salt or an additive.

  含有胺基药用活性化合物的药物物质，以及至少一种醛糖醚和芳香有机酸中的一种作为附加盐或添加剂。
• Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
  申请人：Bristol David William

  公开号：US20080293695A1

  公开（公告）日：2008-11-27

  Drug substances comprising a pharmaceutically acceptable organic acid addition salt 6f amine containing pharmaceutically active compounds useful for the treatment of a therapeutic ailment administration and exhibiting prophylactic properties when employed in non-therapeutic administration.

  包含药用可接受的有机酸盐的药物物质，其中含有药用活性化合物，用于治疗治疗性疾病管理，并在非治疗管理中使用时展现预防性特性。
• Opioid Salts with Release Properties and Characteristics Useful for Abuse Deterrent Drug Product Formulations
  申请人：Pisgah Laboratories, Inc.

  公开号：US20150164835A1

  公开（公告）日：2015-06-18

  A drug substance, and drug products comprising the drug substance, wherein the drug substance is selected from the group consisting of amorphous oxymorphone pamoate; polymorphic oxymorphone pamoate; oxymorphone xinafoate; amorphous codeine pamoate; codeine xinafoate; amorphous levorphanol pamoate; polymorphic levorphanol pamoate; levorphanol xinafoate; amorphous naltrexone pamoate; polymorphic naltrexone pamoate and naltrexone xinafoate.

  一种药物物质和包含该药物物质的药物制品，其中所述药物物质选自以下组合：非晶态的奥沙莫酚帕莫酸盐；多晶型的奥沙莫酚帕莫酸盐；奥沙莫酚西那非酸盐；非晶态的可待因帕莫酸盐；可待因西那非酸盐；非晶态的左旋芬太尼帕莫酸盐；多晶型的左旋芬太尼帕莫酸盐；左旋芬太尼西那非酸盐；非晶态的纳曲酮帕莫酸盐；多晶型的纳曲酮帕莫酸盐和纳曲酮西那非酸盐。
• New derivatives of L-carnitine
  申请人：MAGIS FARMACEUTICI S.P.A.

  公开号：EP0167115A2

  公开（公告）日：1986-01-08

  Novel derivatives of Lcarnitine or of L-acylcarnitines or of esters thereof, obtained by salification with suitable acids or acidic aminoacids, monosalified with potassium ion. These derivatives show cardiotropic properties in the therapy of myocardial anoxia, of ischemia, of arrythmic syndromes, of cardiac failures in general and in cases of increased energy request due to fatigue at cardiac and muscular level.

  左旋肉碱或左旋酰基肉碱或其酯类的新型衍生物，通过与适当的酸或酸性氨基酸盐化，并与钾离子单盐化而获得。 这些衍生物在治疗心肌缺氧、心肌缺血、心律失常综合症、一般心力衰竭以及因心脏和肌肉疲劳而需要更多能量的情况下，具有强心作用。